Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313248 · ClinicalTrials.gov registry record · Phase 2
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer
A Phase 2 study of Breast Neoplasm, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 20
- Study locations
NCT00313248: Completed Phase 2 study of Breast Neoplasm, sponsored by Bayer.
NCT00313248 is a Phase 2 study of Breast Neoplasm that has completed, run by Bayer. The registered enrollment target is 65 participants, below the 160-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00313248, a Phase 2 study of Breast Neoplasm, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) in patients with metastatic breast cancer helps to decrease or stop tumor growth.
Conditions Studied
Interventions
- DRUG Sagopilone (ZK 219477)
Study Locations (20)
California
- - Bakersfield
- - Palm Springs
New York
- - New York
- - Syracuse
Texas
- - Houston
- - San Antonio
Alabama
- - Birmingham
Alaska
- - Anchorage
Arizona
- - Tucson
Arkansas
- - Hot Springs
Colorado
- - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
What the finished NCT00313248 record still lists
NCT00313248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 160-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Breast Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Sagopilone (ZK 219477) is the first listed.
NCT00313248 names 20 study sites across 17 states, led by California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00313248 about?
NCT00313248 is a clinical study titled "Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer". The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) in patients with metastatic breast cancer helps to decrease or stop tumor growth.
What is the current status of trial NCT00313248?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2006-04. Estimated completion is 2008-11.
What conditions does trial NCT00313248 study?
This clinical trial studies the following conditions: Breast Neoplasm.
What interventions are being tested in trial NCT00313248?
The interventions under investigation include: Sagopilone (ZK 219477) (DRUG).
Who is sponsoring clinical trial NCT00313248?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00313248 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00313248's enrollment target sits among peer trials
65 17th of 26 higher than 10 of 26 other Breast Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
RECRUITING · Phase 2
-
Proton Radiation for Stage II/III Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
COMPLETED · Phase 2
-
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
COMPLETED · Phase 2
-
Surviving Daily Life
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia